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Abstract 
Background: Thyroid cancer is generally associated with an excellent prognosis, but there is significant 
long-term morbidity with standard treatment. Some sub-types however have a poor prognosis. 
Metformin, an oral anti-diabetic drug is shown to have anti-cancer effects in several types of cancer 
(breast, lung and ovarian cancer). The proposed mechanisms include activation of the Adenosine 
Mono-phosphate-activated Protein Kinase (AMPK) pathway and inhibition of the mTOR pathway 
(which promotes growth and proliferation). By inhibiting hepatic gluconeogenesis and increasing 
glucose uptake by muscles, metformin decreases blood glucose and circulating Insulin levels. 
Aims: Explore the effect of metformin on the growth and proliferation of thyroid cancer cell lines. 
Methods: The effects of metformin on thyroid cancer cell lines (FTC-133, K1E7, RO82-W-1, 8305C 
and TT) and normal thyroid follicular cells (Nthy-ori 3-1) were investigated using the MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay for cell proliferation; clonogenic 
assays; FACS analysis for apoptosis and cell cycle, H2A.X phosphorylation (γH2AX) assay for DNA 
repair and scratch assay for cell migration. 
Results: Metformin inhibited cell proliferation and colony formation at 0.03 mM and above and 
inhibited cell migration at 0.3 mM. At concentrations of 0.1 mM and above metformin increased the 
percentage of apoptotic cells and induced cell cycle arrest in G0/G1 phase at minimum concentration of 
0.3 mM. Unlike previous reports, no effect on DNA repair response was demonstrated.  
Conclusion: Metformin suppressed growth of all thyroid cancer cell lines, at concentrations 
considered to be within in the therapeutic range for diabetic patients on metformin (<0.3 mM). 
Key words: Metformin, thyroid cancer, human, in vitro 
Introduction 
Thyroid cancer is a relatively uncommon 
malignancy (less than 1% of all cancers registered in 
the UK); but it is the most common endocrine cancer, 
accounting for more than 90% of these tumours [1, 2]. 
The majority of thyroid cancer types belong to the 
category of differentiated thyroid cancer (DTC); the 
prognosis of which is good to excellent with >80% 
surviving 10 years [3]. However, there are concerns 
over long-term morbidity associated with standard 
treatment regimes. For example, thyroid stimulating 
hormone (TSH) suppression in these patients is 
associated with side effects due to high dose of 
Thyroxine used [4].  
Metformin (N’,N’ -dimethybiguanide) is an oral 
antidiabetic drug of the Biguanide class and one of the 
most commonly prescribed drugs worldwide; 
accounting for nearly 120 million prescriptions a year 
[5]. It is the drug of choice in most patients with type 2 
diabetes and has been licensed for use in in UK since 
1958 [6-8]. Several population based studies have 
demonstrated the potential of metformin as a 
chemo-preventative agent in cancer [9-11]. Evans et al 
[9] reported the first such association, demonstrating 
metformin use to be associated with low cancer 
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incidence among type 2 diabetic patients. Other data 
suggests that metformin can reduce the risk of breast 
cancer [12-14], prostatic cancer [13, 15], gastric cancer 
[13, 16], lung cancer [12, 13, 16], pancreatic cancer [13, 
16], and colorectal cancer [13]. There is also 
observational evidence that cancer related mortality is 
reduced in patients on metformin [17-20]. 
Furthermore, investigations of the anti-cancer effects 
of metformin in vitro, using a number of human 
cancer cell lines, including thyroid cancer [21, 22], 
have confirmed these effects, indicating the response 
is in a time and concentration-dependent manner. The 
concentrations however of metformin used in these 
studies were much higher than normal human plasma 
concentrations (0.01-0.3 mM) [23, 24], limiting the 
extrapolation of these findings to clinical practice.  
The possible anti-cancer effects of metformin are 
thought to arise through activating the Adenosine 
Mono-phosphate-activated Protein Kinase (AMPK) 
pathway in several types of cancer [25]. More recently, 
the anti-tumour effect of metformin in breast cancer 
patients correlated with reduced Ki67 expression and 
altered expression of numerous genes [26, 27]. In 
mapping these genes into biological pathways, 
several pathways seem to be involved; in particular 
the TNFR1 and G1/S checkpoint regulation signaling 
pathways were most significantly affected [26]. 
The anti-proliferative action of metformin on 
thyroid cancer [28, 29] may be particularly pertinent, 
as studies suggest metformin decreases TSH level 
without changes in free thyroxine (FT4) [28, 29]. The 
TSH lowering effect of metformin was observed in a 
retrospective case study of 4 hypothyroid patients 
[28], however once metformin use was discontinued 
the level of TSH increased again in all patients. 
Furthermore, in a pilot study, 11 patients with type 2 
diabetes and hypothyroidism on stable thyroxine 
doses, were treated with metformin for 6 months [29]. 
A significantly decreased TSH level was observed 
after 6 months of treatment. The morbidity associated 
with the long term use of high dose thyroxine to 
achieve TSH suppression in patients with 
differentiated thyroid cancer may be countered by the 
use of metformin which is relatively free of side 
effects. This may facilitate a move from TSH 
suppression to TSH replacement therapy. 
The prognosis in certain types of thyroid cancer 
such as medullary thyroid cancer (MTC) and 
anaplastic thyroid cancer (ATC) is intermediate to 
poor with 14% surviving 10 years [3]. New adjuvant 
treatment options are invaluable for these types of 
thyroid cancer. Given recent information on the role 
of metformin as an anti-cancer agent, there is potential 
for metformin to be used as adjuvant treatment in 
these cancer subtypes. To facilitate the development 
of metformin as a potential clinically useful 
anti-cancer drug for thyroid cancer, a detailed 
understanding of its effects on different types of 
thyroid cancer is required. The aim of this study is to 
determine its effects on the growth and proliferation 
of several thyroid cancer and normal cell lines at 
concentrations relevant to clinical settings.  
Material and methods 
Cell culture 
Nthy-ori 3-1 (human thyroid follicular 
epithelium immortalised by transfection with a 
plasmid containing an origin-defective SV40 genome 
(SV-ori)), K1E7 (a subclone of K1 cell line from 
primary papillary thyroid cancer) and FTC-133 
(derived from primary follicular thyroid cancer) were 
available within the department and were 
authenticated by STR profiling. RO82-W-1 (derived 
from metastases follicular thyroid cancer), 8305C 
(derived from primary anaplastic thyroid cancer) and 
TT (derived from primary medullary thyroid cancer) 
were purchased as authenticated cell lines from the 
European Collection of Cell Culture (ECACC). One 
additional breast cancer cell line (MCF7) on which the 
effect of metformin has been reported [30, 31] has 
been included for comparison. This was available in 
the department. All cell lines were cultured in DMEM 
containing 2 g/L glucose supplemented with 10% 
FBS, 1% fungizone and 1% penicillin/streptomycin at 
37 °C in a humidified atmosphere of 95% and 5% CO2. 
Cell proliferation assay 
Cell proliferation was determined using the MTT 
colorimetric metabolic activity assay 
(3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazo
lium bromide ((M5655-1G) purchased from Sigma) 
[32]. For each cell line, cells were seeded in 96 well 
plates (5000 cells per well) and treated in triplicate 
with different concentrations of metformin (Control, 
0.03 mM, 0.1 mM, 0.15 mM, 0.3 m, 1 mM, 5 mM, 10 
mM and 20 mM) (metformin (1,1-Dimethylbiguanide 
Hydrochloride, 5g stored at 4°C purchased from 
Enzo). A broad range of metformin concentrations 
was examined to establish the response to sub 
therapeutic and toxic levels of metformin. 
Proliferation was determined at specific time points 
(1, 2, 3, 4, 5 and 6 days) and the assay was repeated for 
each cell line on 3 separate occasions. For logistic 
reasons, subsequent investigations used a more 
focused range of metformin concentrations.  
Clonal formation assay 
A standard protocol to assess the ability of single 
cells to form a colony was followed as previously 
described [33]. Briefly, each cell line was cultured in 
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10cm petri dishes (500 cells per dish). At 24 hours, 
fresh media containing a more focused range of 
metformin was added (0.03 mM, 0.1 mM, 0.3 mM, 1 
mM, and 5 mM) and cells were incubated for 14 days. 
The assay was repeated for each cell line on 3 separate 
occasions.  
Scratch assay or cell migration assay  
Cells were cultured in silicone inserts with a 
defined cell free gap in each chamber. After 24 hours, 
the silicone insert was removed and the medium were 
changed with medium containing metformin (control, 
0.3 mM and 10 mM) and incubated for 24 hours. The 
cells were washed with PBS and stained with 
methylene blue. For each cell line the experiment was 
repeated on 3 occasions. 
H2AX assay 
Metformin has been previously shown to induce 
DNA damage in mammalian cells [34]. To investigate 
this, the H2AX assay (H2A.X protein gamma-H2A.X) 
was used to measure DNA Double Strand Breaks 
(DNA-DSBs), as phosphorylation of H2A.X is an 
effective measure of DSBs [35], and was performed as 
previously reported [36]. For each cell line, cells were 
seeded (2x 104 cells per slide) into 6 well plates and 
after 24 hours, the wells corresponding to each cell 
line were divided in groups and subject to different 
combinations of treatments:  
a) Metformin (20 mM) + radiation (2Gy IR). 
b) Metformin (0.1 mM) + radiation (2Gy IR). 
c) Radiation (2Gy IR). 
d) Metformin (20 mM). 
e) Metformin (0.1 mM). 
f) Control (not treated with either metformin or IR) 
 
Cells labelled with metformin were treated with 
medium containing metformin (0.1 mM and 20 mM) 
for 6 days. After 6 days of incubation with metformin, 
cells in the IR group were irradiated with 2Gy IR 
using a Cesium137 irradiator (CIS Bio International). 
Post IR 3 times points were assessed (0.5 hour, 1 hour 
and 2 hours), allowing recovery of cells after DNA 
damage. The same time points were also examined in 
the control and metformin only conditions. Cells were 
fixed by adding 1.5 ml of 4% PFA then 2ml of 0.2% 
Triton X-100 in PBS and blocked by adding 1.5ml of 
blocking buffer (10% normal goat serum in PBS). 
100µl of Phospho-histone rabbit anti-у-H2A.X 
(purchased from Cell signaling technology®) was 
added on each coverslip and incubated for 24 hours at 
4°C in a humidity chamber. Cells were washed 3 
times with PBS (5 minutes wash on the rotate shaker). 
They were incubated with 100µl of Cy3 goat 
anti-rabbit IgG (purchased from Invitrogen™, 
Molecular Probes®) in the dark for 1 hour at room 
temperature. The numbers of γH2AX foci were 
counted by using Cytovision software (Newcastle 
upon Tyne, UK) in 100 cells per slide via fluorescent 
microscope with CCD camera at 100x magnification. 
For each cell line, the experiment was repeated in 
triplicate wells and on 3 occasions. 
Flow cytometric analysis for apoptosis assay 
Cells were cultured in 6 well plates (4 x 105 cells 
per well) with 2 ml of medium. Fresh medium 
containing various metformin concentrations (control, 
0.1 mM, 0.3 mM, 1 mM and 10 mM) was added at 24 
hours and incubated for 6 days (37°C, 95% humidity, 
5% CO2). Cells were stained with 5µl of FITC anexin V 
and 5µl of propidium iodide (PI) (FITC Annexin V 
Apoptosis Detection Kit (Cat: 556547) purchased from 
BD Biosciences), and analysed with flow cytometer 
(FACS) (BD Biosciences) using Cell Quest Pro 
software. For each cell line, the experiment was 
repeated on 3 occasions. 
Flow cytometric analysis for cell cycle assay 
Cells were cultured in 6 well plates (4 x 105 cells 
per well) and incubated for 24 hours. Cell lines were 
treated with different concentrations of metformin 
(control, 0.3 mM, 1 mM and 10 mM) and incubated for 
6 days, fixed with 70% ethanol and left overnight at 
4°C. Cells were treated with 50 µl of ribonuclease 
(100µg/mL solution) for 15 minutes at room 
temperature, followed by 200µl of propidium iodide 
(PI) (50 µg/mL stock solution) (Propidium iodide 
1mg/ml (ab14083) was purchased from Abcam) and 
left for 2 hours at 4°C. The samples were analysed 
with flow cytometer (FACS) (BD LSRII) using 
FACSDiva 7.0 software. For each cell line the 
experiment was repeated on 3 occasions. 
Statistical analyses 
All the data was non-parametric and the 
statistical analyses were performed using Graphpad 
Prism software v. 6 for Mac. Kruskal-Wallis test was 
used to compare the results of the experiments for the 
treated (cells treated with different concentrations of 
metformin) and untreated (cells not treated with 
metformin) groups. 
Results 
Metformin inhibits cell proliferation, colony 
formation and migration of thyroid cancer cell 
lines 
Metformin inhibited cell proliferation of all 
thyroid cancer cell lines and Nthy-ori 3-1 at 
concentrations of 0.03 mM and above in a time 
dependent manner (figure 1). The minimum 
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statistically significant concentration of metformin 
that inhibited cell proliferation was 5 mM, at day 3 for 
K1E7 (p=0.01), FTC (p=0.04) and TT (p=0.01); day 4 
for 8305C (p=0.02) and Nthy-ori 3-1 (p=0.02); day 5 for 
RO82-W-1 (p=0.02); and day 1 for MCF7 (p=0.03) 
(data not shown). The anti-proliferative effects on all 
cell lines were significantly enhanced at higher 
concentrations (figure 1b). Even at low physiological 
doses (0.3 mM) longer exposure reduced 
proliferation, although not significantly (figure 1c).  
Inhibition of colony formation, although not 
significant was evident at metformin concentrations 
of 0.03 mM. The minimum statistically significant 
concentration of metformin that was demonstrated to 
inhibit colony formation was 1 mM for K1E7 (p=0.02), 
FTC-133 (p=0.02), RO82-W-1 (p=0.03) and 8305C 
(P=0.02) and 5 mM for Nthy-ori 3-1 cells (p=0.005) 
(figure 2). Colony formation was further decreased by 
increasing the concentration of metformin (figure 2a 
& 2b). The clonogenic assay was also studied on the 
TT cell line but the TT cells did not form colonies. The 
inhibitory effect of metformin can be seen even earlier 
(although not significant) when considering the 
results of cell migrations assays. Metformin inhibited 
cell migration at 24 hours (figure 3), and the effect was 
seen at low physiological concentrations with 0.3 mM 
metformin showing clear inhibition of migration and 
10mM providing evidence of cell stress. Lower 
concentrations of metformin were not investigated. 
Metformin had no effect on the DNA repair in 
thyroid cancer cell lines 
In untreated cells (control), and cells treated with 
metformin (0.1 mM and 20 mM) very low levels of 
phosphorylation of γH2AX foci were detected at the 
comparable post irradiation time points (figure 4a). 
Following radiation for the K1E7 cell line, the 
percentage of cells with more than 10 γH2AX foci was 
99.6% at 30 minutes, 83% at 1 hour and 76% at 2 hours. 
Similar results were observed in FTC-133, RO82-W-1, 
8305C, TT and Nthy-ori 3-1 cells. 
Metformin induces cell cycle arrest and 
apoptosis in thyroid cancer cell lines 
Apoptosis at concentrations of 0.1 mM and 
above was observed for all cell lines and increased in a 
dose dependent manner (figure 4b). Similar results 
were observed in K1E7, FTC-133, RO82-W-1, 8305C, 
Nthy-ori 3-1 and MCF7 but the TT cells already had 
high levels of apoptosis and were more sensitive to 
metformin compared to other cells. The minimum 
statistically significant concentration of metformin 
that induced apoptosis was 10 mM for K1E7 (P=0.01), 
FTC-133 (p=0.007), 8305C 
(P=0.01), TT (P=0.01), Nthy-ori 
3-1 (p=0.04) and MCF7 (P=0.02). 
For the RO82-W-1 cell line, 
statistical significance could not 
be demonstrated at 10 mM of 
metformin (P>0.9). It is also of 
interest that the Nthy-ori 3-1 
normal thyroid cells appeared 
less responsive, with apoptosis 
only marginally increased 
(p=0.04), since cell cycle arrest 
appeared unaltered in Nthy-ori 
3-1 following metformin 
treatment (figure 4c). Thyroid 
cancer cell lines however, in 
particular TT, did demonstrate 
cell cycle arrest with increased 
number of cells in the G0/G1 
phase from a concentration of 0.3 
mM metformin (figure 4c).  
Discussion 
The current study 
evaluated a spectrum of thyroid 
cancer cell lines representing the 
different types seen in clinical 
practice. Initially, proliferation of 
 
Figure 1. The effect of increasing concentrations of metformin on thyroid cancer cell lines over 6 days was accessed by 
the MTT assay. Each data point represents the mean of three experiments performed in triplicate. Error bars show the 
standard error of mean (SEM) for the 3 experiments. Panel A shows proliferation after six days with various 
concentrations of metformin. The supra-physiological and physiological concentrations of metformin decreased thyroid 
cell proliferation in time dependent manner as shown in panel B and C respectively. 
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all cell lines (normal thyroid, thyroid cancers and 
breast cancer cell line MCF-7) was studied following 
exposure to a broad range of metformin 
concentrations, accounting for supra-physiological to 
sub-physiological concentrations (figure 1). Our 
findings showing high dose metformin reducing 
proliferation, support earlier investigations on thyroid 
cancer [21, 37] and the control breast cancer cell line 
MCF-7 [30, 38]. In previous studies however, cells 
were treated with high concentrations of metformin 
for relatively short periods of up to 3 days [22]. In this 
study, metformin was also tested at therapeutic doses 
over a longer time period (1 -14 days). These results 
suggest that at lower physiological doses (0.01-0.3 
mM) [23, 24], metformin although not significantly 
reducing proliferation, does dampen cell proliferation 
in cancer and normal (Nthy-ori 3-1) cell lines (figure 
1c).  
When combining these observations with those 
of the clonogenic assays (figure 2), the dampening 
effect appears enhanced over time, with the lowest 
significant dose (affecting proliferation) dropping 
from 5 mM at day 3 to 1 mM metformin at day 14 
significantly inhibiting colony formation (figures 1 
and 2). The effects of metformin on clonogenicity have 
been intensively investigated in other cancers and also 
thyroid cancer cell lines. As with these earlier studies 
[22, 30, 39] we found that supra-physiological 
concentrations of metformin (1 mM and 5 mM) 
virtually obliterated colony formation for some cell 
lines (8305C and FTC -133). Furthermore we found 
that at concentrations above 5 mM no colonies were 
formed and cells at these concentrations at 14 days 
were dead (data not shown). The action of metformin 
appears wide ranging, and whilst only high doses 
clearly affect proliferation at 24hrs (figure 1b) its effect 
on other processes is evident even at lower doses, 
with 0.3 mM inhibiting migration in the scratch assay 
(figure 3), suggesting that the effects of metformin are 
wide ranging and target different pathways to 
varying degrees.  
 
 
Figure 2. Metformin inhibition of colony formation. Panel A demonstrates percentage of cells that formed colonies (y-axis) in various thyroid cancer cell lines at 14 days over 
a range of concentrations of metformin (x-axis). Each data point represents the mean of 3 experiments done in triplicate. Error bars show the standard error of mean (SEM) for 
the 3 experiments. Panel B shows macroscopic morphology of colony formation of K1E7 cells. After 14 days, pictures were taken of colonies of untreated cells and cells treated 
with various concentrations of metformin.  
 
 
 Journal of Cancer 2017, Vol. 8 
 
http://www.jcancer.org 
1058 
 
Figure 3. Metformin inhibited cell migration of all thyroid cancer cell lines (only data for K1E7 and Nthy-ori 3-1 is presented). After 24 hours, pictures of cells were taken of 
untreated cells and cells treated with metformin (0.3 mM and 10 mM) using the Nikon glipse TS100 microscope at 4x magnification. This experiment repeated 3 times 
independently for each cell lines.  
 
How metformin exerts its action on thyroid 
cancer cells is unclear, but unlike previous 
investigations [34] we did not find that exposure to 
metformin induced DNA damage; even treatment 
with 20mM Metformin for 6 days (prior to measuring 
DNA damage) although significantly reducing 
proliferation did not increase DNA DSB’s in the 
absence of IR (figure 4a). It is thought that the growth 
inhibitory effect of metformin on cancer cell 
proliferation may possibly be through the activation 
of AMPK via activation of LKB1 [40], which causes 
inactivation of mammalian target of rapamycin 
(mTOR) [41]. In numerous human cancers, mTOR 
increased cell growth and proliferation [42]. In 
addition, the growth inhibitory effect of metformin on 
tumour growth may be by indirect effects by 
decreasing circulatory tumour growth factors such as 
glucose [6, 43], insulin [43] and TSH [28, 29]. Insulin 
and glucose play a critical role in tumour growth and 
malignant transformation through stimulation of 
insulin and IGF1 receptors [44-47]. As TSH 
specifically promotes thyroid cancer growth in rat [48] 
and mouse models [49] it may suggest that metformin 
would be specifically effective against thyroid 
cancers. Indeed evidence from this study suggests this 
may be the case, when the observations on apoptosis 
and cell cycle are considered.  
Our findings demonstrated that metformin 
induced apoptosis and cell cycle arrest in thyroid 
cancer cells, increasing both the percentage of 
apoptosis cells and accumulating cells in G0/G1 
phase (figures 4b, 4c). Similar findings were reported 
in other studies on different cancers, including 
thyroid [22, 50, 51]. It is however of interest that the 
normal thyroid cell line Nthy-ori 3-1 seemed to be 
relatively unaffected by metformin even at doses of 10 
mM at 6 days, with only low levels of apoptotic cells, 
negligible necrosis and no change to the number of 
cells in GO/G1 (figures 4 b and c). Furthermore, 
colony formation for all thyroid cancer cell lines was 
inhibited at 1mM, but for Nthy-ori 3-1 significance 
was at 5mM. In contrast, TT (medullary thyroid 
cancer cell line) had naturally high levels of apoptosis, 
which increased dramatically on exposure to 
metformin, and at 10 mM virtually obliterated cell 
division and stalled the majority of the cells in GO/G1 
(figures 4b and 4c). The observations of apoptosis and 
cell cycle assist in explaining the varying proliferative 
responses of the thyroid cancers to metformin. For 
example at high does (20mM), proliferation of TT is 
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blocked even on day 1 (figure 1b), presumably 
because metformin at 10mM induced higher 
apoptosis in this already high turnover cell line, but 
more importantly stalls cells at G0/G1. The high level 
of apoptosis helps to explain the acute sensitivity of 
the TT line to metformin, since low doses of 0.3mM 
(figure 1c) induce the most inhibition for TT (although 
not reaching statistical significance) of all lines at day 
6. Apparently in contrast to this observation high 
doses of 20 mM (figure 1b) have the least effect on TT 
at 6 days. It seems that the high natural rate of 
apoptosis in TT means that it is the most sensitive to 
low doses (figure 1a and c) but that high does will 
have a catastrophic effect even at day 1 (figure 1b) that 
tips the balance in favour of apoptosis and stalls the 
remainder of the cells in GO/G1 (figure 1b and 4 b 
and c). As only one medullary thyroid cancer cell line 
was studied, it is not possible to say if this subtype is 
particularly sensitive, or whether the naturally high 
level of apoptosis affects the response. Recently 
however it has been found that the RET induced 
medullary thyroid cancers increase apoptosis in 
response to therapy targeting the RET oncogene [52, 
53] with inhibition of the MAPK and mTOR 
pathways, supporting other studies suggesting 
metformin targets these pathways [54]. These 
observations in combination with our findings 
suggest that different subtypes of thyroid cancer may 
be more sensitive to metformin than others, although 
it is too early to say whether is clinically applicable. 
Variation in subtypes may explain why a recent study 
has not found any decreased risk of developing 
thyroid cancer for metformin users [55]. 
Although this study did not include surgical 
samples and only immortalized lines were available; 
our current investigation is the first in vitro study that 
looks at longer term exposure to low dose metformin. 
Practically it is not possible to increase the exposure 
due to technical constrains, but our investigation has 
observed that the cumulative effects of metformin 
increase over time for all types of thyroid cancer, and 
suggests that even low sub–physiological doses alter 
behavior and can act to dampen down the 
proliferative response. In combination, our results 
possibly explain why prolonged exposure to 
therapeutic doses, as given to diabetic patients, may 
account for the observed lower level of cancers in 
these populations and are associated with a favorable 
outcome for thyroid cancer [56].  
 
 
Figure 4. Effects of DSBs-DNA and DNA repair, apoptosis and cell cycle arrest. Panel A demonstrated as percentage of cells > 10 γH2AX foci (y-axis) over time in hours (x-axis) 
in thyroid cell lines treated either with metformin (0.1 mM or 20 mM) for 6 days; metformin followed by radiation (2Gy); or with 2Gy radiation only as shown in different colours. 
Panel B shows the percentage of apoptotic, necrotic and viable cells (y-axis) after treatment with different concentrations of metformin for 6 days (x-axis). Panel C shows the 
percentage of viable cells in different phases (y-axis) after treatment with metformin (x-axis) for 6 days. In all panels each value represents the mean of 3 experiments. Error bars 
show SEM reported for the 3 experiments and only 3 cell lines presented. 
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Conclusions 
In summary, metformin inhibits all thyroid 
cancer cell lines, and its action is wide ranging 
impacting on cell proliferation, apoptosis and cell 
cycle arrest, as well as colony formation and 
migration. Our findings suggest that even at low does 
metformin has the capability to exert an effect, which 
over time will be cumulative. For some forms of 
thyroid cancers, such as the medullary thyroid cancer, 
these effects may be enhanced. Further work is aimed 
at understanding the molecular mechanisms of the 
above effects of metformin and its interactions with 
TSH and glucose in the environment.  
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